[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-345286-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-345286-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","simultaneous-inhibition-of-acly-and-ogdh-has-a-synergistic-effect-on-hepatocellular-carcinoma-cell-lines","Simultaneous Inhibition of ACLY and OGDH Has a Synergistic Effect on Hepatocellular Carcinoma Cell Lines","","Hepatocellular carcinoma (HCC) causes high cancer mortality worldwide, and existing therapies lack durable cures, prompting the search for more selective treatments. This study tests synthetic lethality by co-targeting ATP citrate lyase (ACLY) and oxoglutarate dehydrogenase (OGDH) in HCC cells. Using valproic acid (VPA) for OGDH inhibition and bempedoic acid (BA) for ACLY inhibition, the combination strongly synergizes to suppress proliferation in Hep3B and Huh7, with minimal added cytotoxicity in THLE-2 non-cancer cells. The work suggests downstream metabolic effects and highlights the VPA-BA rationale for further validation.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/simultaneous-inhibition-of-acly-and-ogdh-has-a-synergistic-effect-on-hepatocellular-carcinoma-cell-lines/345286/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/simultaneous-inhibition-of-acly-and-ogdh-has-a-synergistic-effect-on-hepatocellular-carcinoma-cell-lines/345286.png","ImageObject",300,407,{"name":42,"@type":43},"Liam","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-15","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",15,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main therapeutic strategy tested in this study?","Question",{"text":63,"@type":64},"The study evaluates synthetic lethality by simultaneously targeting two metabolic genes: ACLY and OGDH, using drug inhibitors in HCC cell lines.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which drugs were used to inhibit ACLY and OGDH?",{"text":68,"@type":64},"Valproic acid (VPA) was used as a pharmacological inhibitor of OGDH, while bempedoic acid (BA) was used as an inhibitor of ACLY.",{"name":70,"@type":61,"acceptedAnswer":71},"What evidence supports synergy and selectivity of the combination treatment?",{"text":72,"@type":64},"Co-treatment produced a strong synergistic inhibition of HCC cell proliferation (Hep3B and Huh7) compared with each drug alone, while showing little increased cytotoxicity in the non-cancerous liver cell line THLE-2.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},345286,1790631570,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":128,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},8796095461564,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","bioRxiv preprint doi: [https://doi.org/10.64898/2026.04.19.716936](https://doi.org/10.64898/2026.04.19.716936); this version posted April 22, 2026. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made  \navailable under aCC-BY-NC-ND 4.0 International license.  \n1 Simultaneous Inhibition of ACLY and OGDH Has a Synergistic  \n2 Effect on Hepatocellular Carcinoma Cell Lines  \n3 Running title: ACLY and OGDH Inhibition Synergizes in HCC Cells  \n4 Mehdi Dehghan Manshadi 1,2,3,+, Nagesh Kishan Panchal 4,+, Lu-Zhe Sun 4,5, Payam Setoodeh 3,*, 5 Habil Zare 6,7,*  \n6 1 Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden  \n7 2 Algorithmic Dynamics Lab, Center for Molecular Medicine, Karolinska Institutet, Stockholm, 8 Sweden  \n9 3 Department of Chemical Engineering, School of Chemical, Petroleum and Gas Engineering, 10 Shiraz University, Shiraz, Iran.  \n11 4 Department of Cell Systems &amp; Anatomy, University of Texas Health San Antonio, San  \n12 Antonio, Texas.  \n13 5 Mays Cancer Center, University of Texas Health San Antonio, San Antonio, Texas.  \n14 6 Glenn Biggs Institute for Alzheimer&\\#39;s &amp; Neurodegenerative Diseases, University of  \n15 Texas Health Science Center, San Antonio, Texas, USA.  \n16 7 Department of Cell Systems and Anatomy, University of Texas Health Science Center, San  \n17 Antonio, Texas, USA.  \n18 + These authors contributed equally to this work and are both first authors.  \n19 * Correspondence should be addressed to Habil Zare: [zare@u.washington.edu](zare@u.washington.edu) and Payam  \n20 [Setoodeh: payamst@shirazu.ac.ir](Setoodeh: payamst@shirazu.ac.ir)[ ](Setoodeh: payamst@shirazu.ac.ir)21  \nbioRxiv preprint doi: [https://doi.org/10.64898/2026.04.19.716936](https://doi.org/10.64898/2026.04.19.716936); this version posted April 22, 2026. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made  \navailable under aCC-BY-NC-ND 4.0 International license.  \n1 Abstract  \n2 Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality worldwide.  \n3 Current treatments offer limited efficacy and no definitive cure, underscoring the urgent need for  \n4 more selective and effective therapeutic strategies. This study investigated the synthetic lethality  \n5 caused by co-targeting two metabolic genes, ATP citrate lyase (ACLY) and oxoglutarate  \n6 dehydrogenase (OGDH), in HCC cells. Using valproic acid (VPA) and bempedoic acid (BA) as  \n7 pharmacological inhibitors of OGDH and ACLY, respectively, we observed a strong synergistic  \n8 effect in inhibiting the proliferation of HCC cell lines (Hep3B and Huh7), compared to using these  \n9 drugs individually. Importantly, this combination treatment exhibited little increased cytotoxicity  \n10 in the non-cancerous liver cell line THLE-2, indicating a degree of selectivity. Our findings are  \n11 consistent with previous reports implicating USP13 as a metabolic regulator of ACLYand OGDH  \n12 in various cancers, suggesting that the inhibition of USP13 may prevent HCC cell proliferation  \n13 primarily through its downstream effects onACLYand OGDH. By directly co-targeting ACLY and  \n14 OGDH, our approach may offer a more precise and safer alternative to USP13 inhibition.  \n15 Additionally, while both VPA and BA have been individually associated with beneficial effects in  \n16 liver disease, their combined application in the context of HCC has not been previously  \n17 investigated. Limitations include the reliance on cell line models, highlighting the need for  \n18 validation in more physiologically relevant systems such as human organoids and animal models.  \n19 Overall, this study provides a compelling rationale for further investigation into ACLYand OGDH  \n20 as a synthetic lethal ","cbCaia888BwM9QPZ","https://ap.wps.com/l/cbCaia888BwM9QPZ","pdf",1094096,"English","# Abstract\n# Introduction","[{\"question\":\"What is the main therapeutic strategy tested in this study?\",\"answer\":\"The study evaluates synthetic lethality by simultaneously targeting two metabolic genes: ACLY and OGDH, using drug inhibitors in HCC cell lines.\"},{\"question\":\"Which drugs were used to inhibit ACLY and OGDH?\",\"answer\":\"Valproic acid (VPA) was used as a pharmacological inhibitor of OGDH, while bempedoic acid (BA) was used as an inhibitor of ACLY.\"},{\"question\":\"What evidence supports synergy and selectivity of the combination treatment?\",\"answer\":\"Co-treatment produced a strong synergistic inhibition of HCC cell proliferation (Hep3B and Huh7) compared with each drug alone, while showing little increased cytotoxicity in the non-cancerous liver cell line THLE-2.\"}]","Simultaneous Inhibition of ACLY and OGDH Has a Synergistic Effect on Hepatocellular Carcinoma Cell Lines | PDF",1790057127,48,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/de8d3cbb22f4ccf48a2560f945d0ccda.webp",983,1272,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bc07bbfc5e3a1d3e05ea903a43629950.webp",982,1270,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/08910ec60e9b4cc7f38ade4fa03a4e7b.webp",981,1269,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4a666d957fbb45200984270ed740cf7b.webp",980,1268]